Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Public ClinicalTrials.gov record NCT06343779. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Cross-over Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adults With Hereditary Angioedema
Study identification
- NCT ID
- NCT06343779
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Enrollment
- 134 participants
Conditions and interventions
Conditions
- Hereditary Angioedema
- Hereditary Angioedema Type I
- Hereditary Angioedema Type II
- Hereditary Angioedema Types I and II
- Hereditary Angioedema Attack
- Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
- Hereditary Angioedema - Type 1
- Hereditary Angioedema - Type 2
- C1 Esterase Inhibitor [C1-INH] Deficiency
- C1 Esterase Inhibitor Deficiency
- C1 Esterase Inhibitor, Deficiency of
- C1 Inhibitor Deficiency
- Hereditary Angioedema - Type 3
- Hereditary Angioedema Type III
Interventions
- Deucrictibant, Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 25, 2024
- Primary completion
- Oct 16, 2025
- Completion
- Oct 16, 2025
- Last update posted
- Nov 20, 2025
2024 – 2025
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Study Site | Birmingham | Alabama | 35209 | — |
| Study Site | Paradise Valley | Arizona | 85258 | — |
| Study Site | Little Rock | Arkansas | 72205 | — |
| Study Site | San Diego | California | 92122 | — |
| Study Site | Santa Monica | California | 90404 | — |
| Study Site | Walnut Creek | California | 94598 | — |
| Study Site | Colorado Springs | Colorado | 80907-6231 | — |
| Study Site | Chevy Chase | Maryland | 20815 | — |
| Study Site | Boston | Massachusetts | 02115 | — |
| Study Site | Detroit | Michigan | 48202 | — |
| Study Site | St Louis | Missouri | 63141 | — |
| Study Site | Hershey | Pennsylvania | 17033 | — |
| Study Site | Dallas | Texas | 75231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 63 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06343779, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 20, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06343779 live on ClinicalTrials.gov.